Anthelmintic resistance in human and animal pathogenic helminths has been spreading in
prevalence and severity. Multidrug resistance is a widespread problem in livestock animals …

Poorly water-soluble drugs demonstrate significant challenge in pharmaceutical
development, which is linked to their limited oral bioavailability and therapeutic efficacy. To …

Cystic echinococcosis (CE) is a zoonosis caused by Echinococcus spp., affecting both
humans and animals' lives. Current treatment of CE by oral administration of albendazole …

Human cystic and alveolar echinococcosis are helmintic zoonotic diseases caused by
infections with the larval stages of the cestode parasites Echinococcus granulosus and E …

Albendazole (ABZ, anti-parasitic active pharmaceutical ingredient) is a crystalline low water-
soluble drug, thus the dissolution rate in gastrointestinal fluids is limited. Consequently, the …

As an emerging novel drug carrier, nanoparticles provide a promising way for effective
treatment of parasitic diseases by overcoming the shortcomings of low bioavailability, poor …

To improve the solubility and anticancer activity of albendazole (ABZ), chitosan (CS)-coated
poly-dl-lactic-co-glycolic acid (PLGA) nanoparticles were developed. CS was used to coat …

Helminthic infections are produced by different types of worms and affect millions of people
worldwide. Benzimidazole compounds such as ricobendazole (RBZ) are widely used to treat …

Since there is no potential, effective vaccine available, treatment is the only controlling
option against hydatid cyst or cystic echinococcosis (CE). This study was designed to …

Lipid nanocapsules (LNCs) are lipid-based nanocarriers that have found application as drug
delivery systems, in diagnostics, and theranostics. They are biocompatible and able to …